Aptorum Group

Aptorum Group EBITDA per Employee

Delisted·Sep 22, 2026

The EBITDA per Employee of Aptorum Group (APM) as of Nov 3, 2026 is -908,764.00 USD. In the previous year, EBITDA per Employee was -1.88 M USD — a change of -51.61% (higher).

EBITDA per Employee

-908,764.00USD

YoY

-51.61%

Last updated:

EBITDA per Employee of Aptorum Group is 2025 -908,764.00 USD. EBITDA per Employee of Aptorum Group was 2024 -1.88 M USD. It decreases by -51.61% higher compared to the previous year.

The Aptorum Group EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-5.34 M USD
Jan 1, 2019
-8.21 M USD
Jan 1, 2020
3.25 M USD
Jan 1, 2021
-12.92 M USD
Jan 1, 2022
-8.15 M USD
Jan 1, 2023
-4.74 M USD
Jan 1, 2024
-1.88 M USD
Jan 1, 2025
-908,764.00 USD
The Aptorum Group EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-908,764.00USD-51.61%
-1.88 MUSD-60.36%
-4.74 MUSD-41.86%
-8.15 MUSD-36.90%
-12.92 MUSD-497.78%
3.25 MUSD-139.55%
-8.21 MUSD+53.79%
-5.34 MUSD+87.53%
-2.85 MUSD+548.23%
-439,117.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptorum Group Stock analysis

What does Aptorum Group do? Aptorum Group Ltd. develops pharmaceutical products targeting unmet medical needs in infectious diseases, cancers, metabolic disorders, and neurology. The company leverages drug discovery platforms to screen approved drug molecules and microbiome-based research for metabolic treatments. It commercializes therapeutic assets through systematic screening and microbiome research, focusing on diseases like infectious conditions, cancer, and metabolic disorders. The company also pursues projects in gastroenterology, women’s health, and surgical robotics, alongside natural supplements for menopausal symptoms. Aptorum Group Ltd. generates revenue by advancing therapeutic and diagnostic projects across multiple disease areas. Its products include treatments for infectious diseases, cancers, and metabolic conditions, developed through drug discovery platforms and microbiome research. The company targets healthcare providers, pharmaceutical partners, and patients seeking innovative treatments for conditions with limited existing options. Segments include infectious disease therapies, cancer treatments, metabolic disorder solutions, and women’s health products. The company’s revenue streams come from the development and commercialization of therapeutic assets. It focuses on drug discovery through systematic screening of approved molecules and microbiome-based research for metabolic diseases. Projects in neurology, gastroenterology, and women’s health contribute to its product portfolio, alongside surgical robotics and natural supplements for menopausal symptoms. Aptorum Group Ltd. serves medical professionals and patients requiring novel treatments for underserved disease areas. Aptorum Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptorum Group stock

EBITDA per Employee of Aptorum Group is -908,764.00 USD in 2025.

EBITDA per Employee of Aptorum Group changed from -1.88 M USD to -908,764.00 USD, representing a -51.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Aptorum Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Aptorum Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Aptorum Group

All Key Metrics — Aptorum Group